Eduardo Bravo: Managing Director and Chief Executive Officer (CEO)
Mr. Eduardo Bravo has more than twenty-five years experience in the biopharmaceutical industry. He has been CEO of TiGenix since May 2011. Prior to joining TiGenix in 2005, he held several senior management positions at Sanofi-Aventis, including Vice President for Latin America, a division with 2000 employees and sales of more than EUR 1 billion. At Sanofi-Aventis he also held senior positions in marketing and sales for Europe and he was general manager for Belgium. Prior to his tenure at Sanofi-Aventis, Mr. Bravo spent seven years at SmithKline Beecham in commercial positions both nationally and internationally. Mr. Bravo holds a degree in Business Administration and an MBA (INSEAD). He is Vice-President of EBE (European Biopharmaceutical Enterprises) and member of the Executive Committee of ARM (Alliance for Regenerative Medicine).
Claudia D’Augusta: Chief Financial Officer (CFO)
Ms. Claudia D’Augusta has more than fifteen years of experience in the field of corporate finance. After completing her degree in Economics and a Ph.D. in Business Administration at the University of Bocconi, Italy, she joined the corporate finance department of Deloitte & Touche in Milan. She later joined Apax Partners in Madrid where she participated in the origination and execution of M&A transactions. She was subsequently finance director of Aquanima (Santander Group). Ms. D’Augusta was a member of the board of directors of Sensia S.L. from April 2005 until April 2008.
Wilfried Dalemans: Chief Technical Officer (CTO)
Mr. Wilfried Dalemans holds a PhD in molecular biology from the Universities of Hasselt and Leuven. Before joining TiGenix, Mr. Dalemans held several senior management positions at GlaxoSmithKline Biologicals, Belgium. As director regulatory strategy and development, he was responsible for the worldwide registration of GlaxoSmithKline's flu franchise. With this firm, he also served as director of molecular biology and research, responsible for the development of nucleic acid and tuberculosis vaccines, as well as immunology research activities. Prior to joining GlaxoSmithKline, Mr. Dalemans worked at Transgène, France, where he was responsible for the cystic fibrosis research program. Mr. Dalemans also served as a supervisory director of Arcarios B.V. and a director of Arcarios NV.
Marie Paule Richard: Chief Medical Officer (CMO)
Dr. Marie Paule Richard has spent more than twenty five years in senior executive positions in pharmaceutical and biotechnology companies. She has held international management positions at Bristol Myers Squibb, Sanofi, GlaxoSmithKline, Sanofi Pasteur and Crucell. Prior to joining TiGenix, Dr. Richard was Chief Medical Officer at AiCuris GmbH, Germany. She has gained global and extensive experience of clinical development strategy and operations across all phases of development, regulatory affairs and pharmacovigilance, involving numerous anti infective and immunomodulatory drugs and biologicals, as well as the life cycle management of marketed products. She has obtained several drug approvals and international license renewals in both Europe and the United States. Dr. Richard holds a medical degree from the University of Nancy, France, and, among other qualifications, a certification in Clinical Immunology.
Maria Pascual - Vice President Regulatory Affairs and Corporate Quality
Dr Maria Pascual holds a degree in Pharmacy from the University of Granada, obtained her PhD in Immunology from the Spanish National Research Council (CSIC), and her Master’s degree in Regulatory Affairs from Autonoma University in Barcelona. She is specialised in regulatory affairs for advanced therapies, is an external adviser to the European Medicines Agency (EMA), and is Chair of the Regulatory Committee of the European Alliance for Advanced Therapies. Dr Pascual has more than 10 years’ experience in cell therapy companies.
Mary Carmen Diez - Vice President Medical Affairs and New Product Commercialisation
A medical doctor specialised in Internal Medicine and Infectious Diseases, Dr Mary Carmen Diez has more than 20 years experience in the biopharmaceutical industry. After completing her Master´s degree in Pharmaceutical Medicine, Dr. Diez joined Pfizer where she was responsible for the clinical development of several anti-infective drugs. Later, she worked in DuPont Pharma as Associate Medical Director, receiving a Business Excellence Award in recognition of her contribution to the business. Prior to joining TiGenix, Dr. Diez was responsible for International Medical Affairs and Marketing for the Pain/CNS and Allergy Divisions of Meda Pharma, where she prepared and executed the successful launch of several products in Europe. She has also been a lecturer in Pharmaceutical Medicine at the University Pontificia de Comillas in Madrid.